An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer According to Tumor-vessel Relationship and CA 19-9 Levels

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.

Inclusion Criteria:

• Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC)
• Between January 2007 and June 2021 at Seoul National University Hospital

Exclusion Criteria:

• Patients who had borderline resectable PDAC with arterial invasion
• Patients who received chemotherapy as initial treatment and did not undergo surgery
• Incomplete follow-up data for analysis